Navigation Links
Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay
Date:10/26/2008

nts regarding the performance, demand and outlook for our products, including our Trofile and our projected revenues. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: risks and uncertainties relating to the performance and acceptance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials for CCR5 inhibitors, entry inhibitors or integrase inhibitors; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether existing levels of reimbursement will be reviewed and reduced by third party payers, including Medicare; whether the draft guidance on Multivariate Index Assays issued by the FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available;
'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
2. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
3. Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments
4. RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial
5. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
6. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
7. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
8. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
9. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
10. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
11. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... -- RadiologyAuction will have their first auction starting May 5 ... the end of the auction on May 27 th ... Cr,s, Agfa and Sony, printers and GE portable x-rays ... equipment will be available at later auctions each month ... buying and selling imaging equipment, the brokers at RadiologyAuction ...
(Date:5/4/2015)... -- Makindus, Inc. a specialty pharmaceutical development company focused on ... has granted orphan drug designation for their lead candidate, ... "We are extremely pleased to now have orphan drug ... for Europe . This complements and ... States for which orphan designation has already ...
(Date:5/4/2015)... , May 4, 2015   HeartWare International, Inc ... invasive, miniaturized circulatory support technologies that are revolutionizing the treatment ... Doug Godshall , is scheduled to present at the ... Las Vegas on Thursday, May 14, ... The live webcast of the Company,s presentation at the conference ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... As part of the Help America ... the first approved candidate with hearing instruments at no ... came into the Beaverton clinic because of hearing concerns. ... those that have hearing loss and limited financial resources ...
... Spectrum Control, Inc. (Nasdaq: SPEC ), a leading ... today that it will release its fourth quarter and fiscal ... close of the market. Following the release, Spectrum Control will ... discuss the Company,s operating results for the quarter and fiscal ...
Cached Medicine Technology:Accurate Hearing & Audiology Clinics / Help America Hear - One Person at a Time 2
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... May 04, 2015 San Diego ... ceremony at their brand new, 13,700 square foot facility ... new building will not only provide fertility treatment and ... also offer community and educational events to a number ... is located next door to their current Carmel Valley/Del ...
(Date:5/4/2015)... Dr. Benjamin Stong of Kalos Facial ... latest non-surgical double-chin eliminator. Dr. Stong is double ... Atlanta to offer Kybella treatments . The FDA ... under the chin, promising to safely dissolve fat deposits ... who sought immediate solutions for their double chin were ...
(Date:5/4/2015)... 04, 2015 Unlike some camps, the Nike Middle ... The goal is to educate first and train second, with ... ensures that the young runners are building the knowledge base needed ... of the topics covered include Effort Based Training, Running Heroes, Running ... to be? This is not a camp where kids come ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Richard ... has been chosen to receive the America’s Best Dentist ... Dr. Champagne’s selection as a top dentist is a ... to continuing education and his compassion for his patients. ... professionals who exemplify excellence in their field. These nominees ...
Breaking Medicine News(10 mins):Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2
... delivery combination selectively crosses the tight barrier that protects the ... to brain tumors, a research team led by scientists from ... the January issue of the Journal of Clinical Investigation ... the targeted particles guide payloads to image tumors, treat tumors, ...
... (HealthDay News) -- HIV-positive teens and young women are more likely ... who do not have HIV, a new study finds. Researchers ... aged 13 to 24, who had been treated at four hospitals ... some more than once, for a total of 96 pregnancies. ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... for profit are more likely to have patients who require ... who need longer times in hospice care, research reveals. ... hospices a flat daily rate, regardless of care needs -- ...
... research from University of Michigan says brain scans showing ... the person whose brain is being scanned. Emily ... recently led a study that scanned the brain activity ... would have an impact on their ability to quit ...
... from human placenta left over from live births and ... one kind of melatonin receptor, MT1. This potentially therapeutic ... laboratory test tube and animal models of stroke. ... with melatonin receptor MT2. Researchers from the University ...
... HealthDay Reporter , TUESDAY, Feb. 1 (HealthDay News) ... from meningococcal meningitis, a potentially deadly infection of the ... up-to-date whooping cough vaccines in light of recent outbreaks, ... American Academy of Pediatrics issues updated vaccination guidelines annually. ...
Cached Medicine News:Health News:Targeted particle fools brain's guardian to reach tumors 2Health News:Targeted particle fools brain's guardian to reach tumors 3Health News:Targeted particle fools brain's guardian to reach tumors 4Health News:HIV Linked to Higher Pregnancy Rate in Young Women 2Health News:For-Profit Hospices May Prefer Certain Types of Patients: Study 2Health News:For-Profit Hospices May Prefer Certain Types of Patients: Study 3Health News:Brain scans predict likely success when it comes to quitting smoking 2Health News:Transplanted human placenta-derived stem cells show therapeutic potential in stroke models 2Health News:Pediatricians Issue New Vaccination Recommendations 2Health News:Pediatricians Issue New Vaccination Recommendations 3
4 hour identification of over 70 medically important, oxidase-negative, gram-negative bacilli, including E. coli, based on enzyme technology....
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Medicine Products: